nafamostat has been researched along with Pancreatic Neoplasms in 21 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of regional arterial infusion of the synthetic serine protease inhibitor nafamostat mesilate combined with gemcitabine for the treatment of patients with unresectable locally advanced or metastatic pancreatic cancer." | 2.78 | Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. ( Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Tsutsui, N; Uwagawa, T; Yanaga, K, 2013) |
| "The aim of this study was to investigate prognostic factors of survival for patients with unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy." | 2.77 | Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. ( Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K, 2012) |
| "Patients with previously untreated pancreatic cancer received gemcitabine (1 000 mg/m(2) i." | 2.74 | A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. ( Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K, 2009) |
| "Biliary cancer and pancreatic cancer are considered to be difficult diseases to cure." | 2.52 | Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. ( Uwagawa, T; Yanaga, K, 2015) |
| "Pancreatic cancer is a highly lethal malignancy and one of the leading causes of cancer-related death." | 1.43 | Mast Cell Tryptase Contributes to Pancreatic Cancer Growth through Promoting Angiogenesis via Activation of Angiopoietin-1. ( Gao, C; Guo, X; Shi, J; Xue, R; Zeng, Q; Zhai, L, 2016) |
| "In vivo, orthotopic pancreatic cancer mice (BALBc nu/nu) were divided into four groups: control (n = 13), NM (n = 13), GEM/nPTX (n = 13), and triple combination (n = 13)." | 1.43 | New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. ( Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K, 2016) |
| "With a diagnosis of unresectable pancreatic cancer, the patient received gemcitabine and TS-1 with arterial infusion of nafamostat mesilate." | 1.42 | Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case. ( Fujiwara, Y; Futagawa, Y; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015) |
| "In vivo, we established a xenograft pancreatic cancer model in mice by subcutaneous injection of MIAPaCa-2 and AsPC-1." | 1.39 | Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice. ( Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K, 2013) |
| "Paclitaxel (PTX) is a useful treatment for peritoneal dissemination of malignant tumors." | 1.37 | Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer. ( Fujiwara, Y; Furukawa, K; Iida, T; Misawa, T; Ohashi, T; Shiba, H; Shimada, Y; Uwagawa, T; Yanaga, K, 2011) |
| "NF-kappaB activation in pancreatic cancer cells treated with various agents was examined by electrophoretic mobility shift assay (in vitro) and immunohistochemistry by investigating the location of p65 in cancer cells (in vivo)." | 1.35 | Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. ( Chiao, PJ; Gocho, T; Hirohara, S; Misawa, T; Uwagawa, T; Yanaga, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Uwagawa, T | 18 |
| Sakamoto, T | 3 |
| Gocho, T | 7 |
| Shiba, H | 13 |
| Onda, S | 2 |
| Yasuda, J | 2 |
| Shirai, Y | 4 |
| Hamura, R | 2 |
| Furukawa, K | 10 |
| Yanaga, K | 17 |
| Ikegami, T | 1 |
| Shiozaki, H | 1 |
| Homma, S | 1 |
| Hayashi, K | 1 |
| Yoshida, K | 1 |
| Sagawa, Y | 1 |
| Kamata, Y | 1 |
| Ito, M | 1 |
| Saito, N | 2 |
| Takada, N | 1 |
| Sugano, H | 1 |
| Ohashi, T | 9 |
| Fujiwara, Y | 9 |
| Futagawa, Y | 1 |
| Misawa, T | 9 |
| Iwase, R | 5 |
| Haruki, K | 7 |
| Guo, X | 1 |
| Zhai, L | 1 |
| Xue, R | 1 |
| Shi, J | 1 |
| Zeng, Q | 1 |
| Gao, C | 1 |
| Horiuchi, T | 1 |
| Ito, R | 2 |
| Wakiyama, S | 1 |
| Hirohara, S | 3 |
| Sadaoka, S | 2 |
| Chiao, PJ | 2 |
| Iida, T | 4 |
| Shimada, Y | 3 |
| Kobayashi, H | 1 |
| Tsutsui, N | 1 |
| Kitagawa, H | 1 |
| Tani, T | 1 |
| Takamura, H | 1 |
| Kayahara, M | 1 |
| Ohta, T | 1 |
| Li, Z | 1 |
| Chang, Z | 1 |
| Xia, Q | 1 |
| Peng, B | 1 |
| Sclabas, GM | 1 |
| Ishiyama, S | 1 |
| Hung, MC | 1 |
| Evans, DB | 1 |
| Abbruzzese, JL | 1 |
2 reviews available for nafamostat and Pancreatic Neoplasms
| Article | Year |
|---|---|
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; C | 2015 |
[Quality of life in surgical treatment of pancreatic cancer].
Topics: Benzamidines; Drainage; Guanidines; Humans; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasm | 2006 |
5 trials available for nafamostat and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Gu | 2022 |
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Gu | 2022 |
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Gu | 2022 |
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Gu | 2022 |
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined | 2021 |
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzam | 2009 |
Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Ge | 2013 |
Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Ge | 2012 |
14 other studies available for nafamostat and Pancreatic Neoplasms
| Article | Year |
|---|---|
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Topics: Adenocarcinoma; B7-H1 Antigen; Benzamidines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, | 2018 |
Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice.
Topics: Animals; Benzamidines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; | 2019 |
Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
Topics: Antimetabolites, Antineoplastic; Benzamidines; Deoxycytidine; Gemcitabine; Guanidines; Humans; Male; | 2015 |
Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
Topics: Animals; Apoptosis; Benzamidines; Cell Cycle Checkpoints; Cell Line, Tumor; Guanidines; Humans; Male | 2016 |
Mast Cell Tryptase Contributes to Pancreatic Cancer Growth through Promoting Angiogenesis via Activation of Angiopoietin-1.
Topics: Angiopoietin-1; Animals; Benzamidines; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2016 |
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2016 |
Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Benzamidines; Cell Cycle; Deoxycytidine; Drug Therapy, Com | 2009 |
Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamidines; Blotting, Western; Cell Cycle; Cell Line, T | 2010 |
Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic | 2011 |
Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.
Topics: Adenoviridae; Animals; Benzamidines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibi | 2011 |
Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
Topics: Animals; Benzamidines; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Enzym | 2011 |
Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Topics: Adenoviridae; Analysis of Variance; Animals; Benzamidines; Blotting, Western; Cell Cycle; Cell Line, | 2013 |
Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Cell Line, Tumor; | 2013 |
Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzamidines; Caspase 8; Cell Line, Tumor; Enzyme | 2007 |